GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patientâ€™s immune systemâ€™s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	12.09M 10.63M 9.88M 9.08M 17.04M 1.17B 17.34M 118M 46.07M 571M 45.38M 44.4M 1.98B	P/E 2026 *	-0.99x	P/E 2027 *	-1.24x
Enterprise Value	12.09M 10.63M 9.88M 9.08M 17.04M 1.17B 17.34M 118M 46.07M 571M 45.38M 44.4M 1.98B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	93.99%	Yield 2026 *	-	Yield 2027 *	-

06-30	GT Biopharma Reports Integration Of AI-Based Tools Across Discovery And Engineering Of Tumor-Targeting NK Cell Engagers And Multi-Domain Proteins	CI
06-08	Gt Biopharma Advances Three Trike Drug Candidates into Human Trials and Doses First Patient in Phase 1 Trial of Gtb-5550	CI
06-01	GT Biopharma, Inc. Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives	CI
05-29	GT Biopharma Advances Three Trike Drug Candidates into Human Trials	CI
05-15	GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-14	GT Biopharma announces first patient dosed in phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors	RE
05-14	Gt Biopharma Inc Announces First Patient Dosed in Phase 1 Trial of Gtb-5550, A B7-H3-Targeted Natural Killer (Nk) Cell Engager for Solid Tumors	CI
04-07	GT Biopharma, Inc. Enters into Investigator Initiated Clinical Trial Agreement with Regents of the University of Minnesota	CI
03-02	GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-01	GT Biopharma, Inc. Auditor Raises 'Going Concern' Doubt	CI
02-03	GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug for GTB-5550 TriKE, B7-H3-Targeted Natural Killer Cell Engager for Solid Tumors Expressing B7-H3	CI
02-03	GT Biopharma gets FDA IND clearance for GTB-5550 TRiKE, B7-H3-targeted NK engager for B7-H3+ solid tumors	RE
01-15	GT Biopharma, Inc. Announces IND Submission for GTB-5550 TriKE, B7-H3-Targeted Natural Killer Cell Engager for B7-H3 Expressing Solid Tumor Cancers	CI

23-01-05	EF Hutton Starts GT Biopharma at Hold With $2 Price Target	MT
22-09-13	HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating	MT
22-08-12	Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9	MT
22-01-24	B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating	MT
21-06-24	GT BIOPHARMA : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating	MT

06-30	A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs	AQ
06-12	After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell	AQ
06-08	Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet	AQ
06-01	GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives	AQ
05-15	GT Biopharma Reports First Quarter 2026 Financial Results	AQ

24-04-30	Caterpillar deja París, el cacao está menos caliente
24-04-30	Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud

Oxis International Stock Euronext Paris

Stocks

US6918295014

Biotechnology & Medical Research

Valuation: Oxis International

Latest news : Oxis International

Analysts' recommendations: Oxis International

Press Releases: Oxis International

News in other languages: Oxis International

Quotes and Performance

Managers and Directors: Oxis International

Bio Therapeutic Drugs

Financials

Company Profile

Manager	Title	Age	Since
Michael Breen CEO	Chief Executive Officer	64	2022-03-01
Alan Urban DFI	Director of Finance/CFO	57	2024-06-02

Director	Title	Age	Since
Michael Breen CHM	Chairman	64	2021-12-14
Charles Casamento BRD	Director/Board Member	81	2023-04-30
Hilary Kramer BRD	Director/Board Member	62	2025-05-06

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OXIS INTERNATIONAL	-99.71%	-99.61%	-	-	12.46M
WUXI APPTEC CO., LTD.	+1.23%	+0.35%	+51.62%	+87.98%	55.27B
ARGENX SE	+5.09%	+6.24%	+63.15%	+62.06%	54.15B
INSMED INCORPORATED	+0.72%	-0.05%	+3.84%	+409.54%	23.11B
BIONTECH SE	+0.25%	+0.55%	-19.67%	-15.22%	23.22B
WUXI BIOLOGICS (CAYMAN) INC.	-0.61%	+5.19%	+30.32%	-4.07%	20.33B
GENMAB A/S	-0.37%	+0.71%	+31.36%	-31.61%	17.91B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.96%	+5.98%	+32.93%	+545.99%	15.76B
PHARMAESSENTIA CORPORATION	-2.54%	-8.73%	+164.11%	+289.45%	15B
EXELIXIS, INC.	+1.22%	-0.05%	+22.58%	+182.63%	13.82B
Average	-9.61%	+0.71%	+42.25%	+169.64%	26.51B
Weighted average by Cap.	+1.26%	+2.77%	+43.49%	+134.79%

	2026 *	2027 *
Net sales	-	-
Net income	-12.27M -10.79M -10.02M -9.22M -17.29M -1.19B -17.6M -120M -46.76M -580M -46.06M -45.06M -2.01B	-12.7M -11.17M -10.38M -9.54M -17.9M -1.23B -18.22M -124M -48.39M -600M -47.67M -46.64M -2.08B
Net Debt	-	-